Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06818643 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 4 months later Oct 25, 2028 → Mar 7, 2031
See other at-risk trials from Merck (MSD)

Record History

  1. Primary completion pushed from Oct 25, 2028 to Mar 7, 2031 Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC · Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 2 of 13 entries · 1 more Show 4 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 2 of 13 entries
    • Study sites revised (49)
  2. Site details revised at 1 of 49 sitesv29
  3. Study sites: 48 to 49v28
  4. Trial sites expanded: 45 → 48 locationsv27
  5. Trial sites expanded: 42 → 45 locationsv26
Show 24 earlier versionsHide 24 earlier versions
  1. Site contacts updated at 1 of 42 sitesv25
  2. Site contacts updated at 2 of 42 sitesv24
  3. Study sites revised (42)v23 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 40 to 42v22
  5. Enrollment target: 180 to 270 Primary completion date: Jan 28, 2028 to Oct 25, 2028 · Study sites: 39 to 40 · Completion date: Jan 28, 2028 to Mar 25, 2031 · 2 morev21 Show 5 more changesShow less
    • Primary completion date: Jan 28, 2028 to Oct 25, 2028
    • Study sites: 39 to 40
    • Completion date: Jan 28, 2028 to Mar 25, 2031
    • Eligibility criteria shortened, about 164 words
    • Secondary endpoints revised (13)

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 38 to 39v20
  7. Study sites: 37 to 38v19
  8. Study sites: 34 to 37v18
  9. Study sites: 33 to 34v17
  10. Study sites: 31 to 33v16
  11. Study sites: 26 to 31v15
  12. Study sites: 25 to 26v14
  13. Study sites: 23 to 25v13
  14. Study sites: 21 to 23v12
  15. Study sites: 20 to 21v11
  16. Study sites: 16 to 20v10
  17. Secondary endpoints: 7 to 13v9 See this version in full on ClinicalTrials.gov ↗
  18. Study sites: 13 to 16v8
  19. Study sites: 10 to 13v7
  20. Study sites: 8 to 10v6
  21. Study sites: 7 to 8v5
  22. Study sites: 6 to 7v4
  23. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 6 · Start date changed from estimate of Mar 24, 2025 to Mar 25, 2025v3 Show 2 more changesShow less
    • Study sites: 0 to 6
    • Start date changed from estimate of Mar 24, 2025 to Mar 25, 2025
  24. Secondary endpoints: details revised at 1 of 7 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Trial Details
NCT Number NCT06818643
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Advanced Solid Tumors, Malignant Neoplasm
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov